Journal
CELL HOST & MICROBE
Volume 29, Issue 7, Pages 1063-1075Publisher
CELL PRESS
DOI: 10.1016/j.chom.2021.06.009
Keywords
-
Categories
Funding
- NIH/NIAID [R01AI130398, R01AI127877]
- Crown Family Foundation
- NIH [1U54CA260517]
Ask authors/readers for more resources
Human immune responses to SARS-CoV-2 have made significant progress in understanding the nature of antibody responses and their role in protecting against infection or modulating the severity of COVID-19, aiding in the development of effective vaccines. However, important questions remain unanswered regarding the duration and effectiveness of antibody responses, immunity differences between infection and vaccination, cellular basis for serological findings, and the potential impact of viral variants on current immunity.
Antibodies, and the B cell and plasma cell populations responsible for their production, are key components of the human immune system's response to SARS-CoV-2, which has caused the coronavirus disease 2019 (COVID-19) pandemic. Here, we review findings addressing the nature of antibody responses against SARS-CoV-2 and their role in protecting from infection or modulating COVID-19 disease severity. In just over a year, much has been learned, and replicated in independent studies, about human immune responses to this pathogen, contributing to the development of effective vaccines. Nevertheless, important questions remain about the duration and effectiveness of antibody responses, differences between immunity derived from infection compared to vaccination, the cellular basis for serological findings, and the extent to which viral variants will escape from current immunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available